Intracellular and Extracellular Roles of Granzyme K

Annemiek C. Bouwman1†, Kim R. van Daalen2†, Sandra Crnko1, Toine ten Broeke1 and Niels Bovenschen1,3*

1 Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands, 2 Cardiovascular Epidemiology Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, United Kingdom, 3 Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Granzymes are a family of serine proteases stored in granules inside cytotoxic cells of the immune system. Granzyme K (GrK) has been only limitedly characterized and knowledge on its molecular functions is emerging. Traditionally GrK is described as a granule-secreted, pro-apoptotic serine protease. However, accumulating evidence is redefining the functions of GrK by the discovery of novel intracellular (e.g. cytotoxicity, inhibition of viral replication) and extracellular roles (e.g. endothelial activation and modulation of a pro-inflammatory immune cytokine response). Moreover, elevated GrK levels are associated with disease, including viral and bacterial infections, airway inflammation and thermal injury. This review aims to summarize and discuss the current knowledge of i) intracellular and extracellular GrK activity, ii) cytotoxic and non-cytotoxic GrK functioning, iii) the role of GrK in disease, and iv) GrK as a potential therapeutic target.

Keywords: cytotoxic cells, granzyme K, cytotoxicity, inflammation, disease

INTRODUCTION

Granzymes are a family of serine proteases traditionally known for their role in promoting cytotoxicity of foreign, infected or neoplastic cells. Granzymes induce (apoptotic) cell death mediated by a collective of cytotoxic lymphocytes (CLs) (e.g. cytotoxic T lymphocytes (CTLs), natural killer (NK) cells). There are five human granzymes (granzyme A (GrA), GrB, GrH, GrK and GrM) currently identified, whereas mice have ten known granzymes (GrA-G, GrK, GrM and GrN) (1). Whilst human granzymes are homologous in amino acid sequence (40%), they vary in their primary substrate specificity, function(s) and are uniquely expressed in distinct cell types (2, 3). Upon activation, CTLs and NK cells induce apoptosis via the extrinsic death-receptor pathway or the granule secretory pathway involving the pore-forming protein perforin and granzymes (4). The latter are collectively stored in intracellular granules and delivered by CLs to the immunological synapse after recognition of a target cell (4). Consecutively, aided by perforin, granzymes are released in the cytosol of target cells, where they cleave intracellular substrates and activate signaling pathways (4).

Although granzymes are traditionally described as primarily being involved in immune-targeted cell death, emerging clinical and biochemical evidence suggests additional roles for granzymes (5, 6). For example, GrB acts in autoimmune diseases by directly cleaving or aiding in the production of autoantigens (7). Additionally, various granzymes (GrA, GrB, GrM) are reported to induce
inflammation and interfere in viral replication (3, 8–10) and all human granzymes target hnRNP K which reduces tumour cell viability (11). Apart from intracellular activity, granzymes exist in the extracellular space, thereby having the potential to exert effects on both sides of the cellular membrane. Illustratively, GrA, which shares homology and enzymatic activity with GrK, and GrB can degrade extracellular matrix (ECM) possibly leading to cell death through anoikis (12). Extracellular granzymes are particularly upregulated in diseased individuals (e.g. in skin inflammation, viral and bacterial infections) (9, 13–16). Combined, this supports the current view that granzymes possess extracellular roles in addition to their traditionally described intracellular roles. Similarly, it has been suggested that GrK has non-cytotoxic roles, including the augment of GrA-induced pro-inflammatory processes (17, 18).

In comparison to GrA (a trypase) and GrB (an asp-ase), little is known about the molecular functioning of the only other trypase in the granzyme family; GrK (19). Human GrK was first discovered in 1988 after purification from human peripheral blood mononuclear cells (20). GrK is expressed by CTLs, natural killer T cells (NKT), γδ T cells and CD56<sup>bright</sup> NK cells (21–23). Similar to its closest homolog GrA, GrK displays trypase-like activity cleaving substrates after basic Arg or Lys (24). Since GrA and GrK are both trypsases and have some substrates in common, GrK has long been viewed as a redundant enzyme for GrA. However, this concept is now debated due to the unique substrates and functionality of GrK (25). The GrK gene (GZMK) is closely linked to GZMA on chromosome 5, likely originating from gene duplication (1, 26). Human GrK is synthesized as a pre-pro-granzyme (zymogen) containing a signal dipeptide directing pre-pro-GrK to the endoplasmic reticulum (ER) (27). Removal of the dipeptide [e.g. by granular cathepsin (28)] results in conformational change and subsequent catalytic activation (29). Mature GrK exists as a monomer with four disulfide bridges and no free cysteine (Cys) residues. The three-dimensional structure highly relates to trypsin and other related granzymes (27). GrK contains a heparin-binding site, an activation domain with proteolytic activity and a nonspecific substrate-binding template strand (24, 30). Various GrK substrates have been reported, including nucleosome assembly protein SET, heterogeneous nuclear ribonucleoprotein (hnRNP) K, β-tubulin and α-tubulin (25, 31). Inter-alpha inhibitor 1 (Iα1p), which circulates in the plasma of healthy individuals, is a physiological GrK inhibitor (32). Similar to the other granzymes, the traditional role of GrK is debated and (extracellular) functions of GrK in promoting inflammation and infections are emerging.

Both intra- and extracellular GrK target physiological substrates (Table 1), dependent or independent on its catalytic activity. Furthermore, GrK is released in plasma of patients suffering from e.g. autoinflammatory diseases, suggesting a potential role in the biological impact of the diseases. Yet, little has been described on the potential non-cytotoxic and extracellular functioning of GrK thus far. Therefore, this review aims to comprehensively describe the diverse roles of Granzyme K and its potential as therapeutic target.

### INTRACELLULAR GRK ACTIVITY

#### Cytotoxicity

Pioneering research on rat GrK initially classified GrK as a DNA-fragmenting protease and identified it as fragmentin. This was a result of the observation that GrK induced YAC-1-derived DNA to be cleaved in oligonucleosome-sized fragments resulting in the formation of severe chromatin condensation (42). The first in vitro study on the apoptotic capacity of human GrK combined with perforin suggested that it induces non-apoptotic cell death via provoking mitochondrial dysfunctioning and generation of reactive oxygen species (ROS) (43). Further in vitro studies showed that cleavage of several intracellular GrK substrates results in cytotoxicity (Figure 1), including proteins of the SET complex, BH3 interacting-domain death antagonist (Bid), vasolin-containing protein (VCP) and p53.

Early studies on human GrK showed that GrK activates caspase-independent apoptosis by cleaving the nucleosome assembly protein (NAP) SET in its recombinant and native form or in intact cells in vitro (33). This results in the disruption of SET and loss of inhibition of GrK-activated DNase (GAAD) functioning. Consequently, the GAAD NM23H1 nicks chromosomal DNA, resulting in chromatin condensation and apoptotic nuclear morphology comparable to GrA (33). GrK also targets other SET complex proteins including DNA-binding protein HMG2 and redox factor-1/apurinic apyrimidinic endonuclease 1 (Ape1), an endonuclease antagonizing ROS generation (33, 35). The initial suggestion that GrK and GrA show redundant specificity and function is supported by the observation that both granzymes cleave SET, Ape1 and HMG2 with similar degradation fragments (Table 1) (33). As a physiological substrate of GrK, Ape1 cleavage facilitates intracellular accumulation of ROS. This may be the first step in GrK-mediated cell death as ROS accumulation takes part in a positive feedback loop wherein disruption of mitochondria leads to additional ROS release, also known as ROS-induced ROS release (44). GrK reportedly induces ROS accumulation in vitro, supporting this hypothesis (34, 43, 44).

Other potential pathways triggering GrK-induced apoptosis depend on mitochondrial damage and ER stress, both resulting in ROS accumulation (36, 37). Like GrB, human GrK is shown to degrade recombinant and native Bid to truncated Bid (tBid) in vitro, enabling it to disrupt the outer mitochondrial membrane (34). This leads to release of pro-apoptotic cytochrome c and endonuclease G, suggesting GrK caspase-mediated apoptosis. These results are in contrast with earlier findings suggesting rat GrK does not trigger cytochrome c release in vitro (45). This may be explained due to granzyme orthologues not completely sharing substrate specificity (46). Furthermore, VCP is an important component of the endoplasmic-reticulum-associated protein degradation (ERAD) pathway that eliminates misfolded proteins and has ATPase activity. In vitro GrK can bind and cleave VCP, as well as other ERAD components Ufd1 and Npl4 (36). The resulting inhibition of ERAD leads to the accumulation of misfolded proteins and ER stress (36). Adaptive responses to limit ER stress include nutrient starvation and transcriptional activation of RNases which degrade misfolded proteins (47). When the adaptive response is not...
sufficient to overcome ER stress, the cell will undergo apoptosis (47). ER stress, as well as tBid-mediated disruption of the outer mitochondrial membrane, may lead to additional accumulation of ROS (34). Lastly, p53 is a physiological target of GrK, processing p53 to three pro-apoptotic fragments: p13, p35 and p40 (37). Once cleaved into their active form, these products cause mitochondrial disruption and upregulation of p21, PG13 and MDM2 transcription (37). Intracellular GrK-challenged tumor cells are killed in a p53-dependent manner (37).

These results identify various intracellular GrK substrates \textit{in vitro}, including SET, Bid, Ape1, VCP and p53 leading to cytotoxicity in caspase-independent ways through DNA damage,
mitochondrial damage and ROS accumulation (Figure 1). Importantly, next to sharing some substrates with GrA (Table 1), GrK has thus shown to possess its own unique functions cleaving specific substrates in addition to being a functional GrA back-up.

Non-Cytotoxic Roles

In contrast to in vitro studies on human and rat GrK (42), in vitro mice studies report no cytotoxicity of mouse GrK (mGrK) (17). Analyzing the same markers of apoptosis as in previous studies (phosphatidylserine externalization, mitochondrial membrane integrity and ROS accumulation), mGrK concentrations up to 600 nM (with delivery agent) and 1200 nM (without delivery agent) did not induce apoptosis in mouse embryonic fibroblasts and EL4 cells (17). Similar results were obtained in vivo using GrK-deficient (GrK−/−) mice (48). When comparing the apoptotic potential of GrK−/− mice with WT mice, no essential role in cytotoxicity for GrK was found (48). Hence, the apoptotic potential of GrK has remained controversial (48).

This controversy has also been reported for GrA. Despite early studies demonstrating GrA induces cell death in vitro (49, 50), others identified GrA as a pro-inflammatory granzyme, unable to induce apoptosis in vivo in mice and humans (51). For GrB, nanomolar concentrations were sufficient to induce apoptosis in Jurkat cell-free extracts, suggesting high cytotoxicity (52). In studies proposing GrA’s and GrK’s cytotoxic activity however, micromolar concentrations are required, suggesting lower cytotoxicity than GrB (53). Whilst granzymes are conserved in various organisms, differences in granzyme substrate specificity and function among species may explain this conflicting data. Further in vivo studies on human GrK using physiological GrK levels are needed to establish its cytotoxic potential.

GrK also targets intracellular non-cytotoxic substrates such as importin α1 or β in vitro, destabilizing their association to generate the ternary import complex for transportation of cytoplasmic cargos (α1/β dimer) (38) (Figure 1). Proteomic studies furthermore identified intracellular substrates β-tubulin, the microtubule network protein, and the pre-mRNA-binding protein hnRNPK (25) (Table 1). Both proteins play important roles in cellular physiology making them relevant for cell survival. Cleavage of β-tubulin may impair tubulin polymerization, whereas cleavage of hnRNPK may inhibit or rescue the translation of proteins involved in cell death. Cleavage of these proteins raised the potential of a new cell death pathway induced by GrK different from GrA (25). hnRNPK downregulation was shown to promote a mixture of exon inclusion and exon skipping events affecting various apoptotic proteins (54). However, thus far, the physiological role of β-tubulin and hnRNPK cleavage remains unclear (25).

GrK is suggested to augment GrA-induced pro-inflammatory processes by cleaving the same substrates differentially - based on the high display of GrK substrate specificity (17) (Table 1). This may be through stimulation of target cells to secrete pro-inflammatory cytokines. mGrK induces pro-inflammatory interleukin-1β (IL-1β) maturation and secretion in LPS-sensitized peritoneal macrophages (PEMO) in vitro (17). In this research, it was not established whether this effect was dependent on intra- or extracellular modulation by mGrK. However, nanomolar, physiological concentrations of mGrK in combination of perforin were sufficient to induce IL-1β release (>30 nM), whereas only high, non-physiological concentrations of mGrK alone induced IL-1β release (600 and 1000 nM) (17). Hence, mGrK may induce IL-1β release of primed PEMOs dependent on intracellular modulation. To date, no additional intracellular substrates of GrK have been described. All in all, several non-cytotoxic intracellular targets and functions have been described for GrK. These include importin α1 or β, β-tubulin and hnRNPK.

EXTRACELLULAR GRK ACTIVITY

GrK circulates in the extracellular space in different forms. In healthy individuals, GrK can form complexes ranging from 150-250 kDa (inactive multimimer), whereas its free form is 26 kDa (monomer) (14). Multiple mechanisms have been suggested to result in extracellular GrK release. These include i) escape from the immunological synapse, ii) granzyme release post degranulation, iii) degranulation induced by chemokines or iv) cytokines and v) granzyme release following integrin-ECM proteins interaction (55). Extracellular GrK, when administered in the absence of a delivery agent such as perforin, is not considered cytotoxic in vitro (39, 40, 56). Furthermore, GrK, among other cell types, is expressed by CD56bright+ NK cells, and classically activated macrophages, which either express none or negligible levels of perforin (21, 56). The presence of GrK in the extracellular space and its synthesis in the absence of perforin suggests GrK has additional functions in addition to its classically described perforin-mediated intracellular activity. Under physiological conditions, little in vivo evidence of GrK-mediated extracellular cleavage of substrates exist. Yet, accumulating in vitro evidence points to the roles of GrK in endothelial activation and the induction of a pro-inflammatory cytokine response.

Endothelial Activation

Following an infection the endothelium undergoes changes, defined by the expression of cell-surface adhesion and endothelial leukocyte adhesion molecules, to participate in the inflammatory response - a process known as endothelial activation. GrK activates the endothelium through modulation of transmembrane receptors. Through cleavage, GrK activates a member of the protease activated receptor (PAR) family, PAR-1 in vitro, which is considered an important activator of endothelium (39, 57). PAR-1 is activated by cleavage of its N-terminal by proteases. GrK-mediated endothelial activation is abrogated by interference of the neutralizing antibody for PAR-1, ATAP-2, suggesting GrK-mediated endothelial activation is dependent on cleavage and activation of PAR-1 (39, 40, 57). Differential responses from the endothelium are induced depending on the cleavage site of the receptor, conferred by the co-receptor and protease utilized (e.g. thrombin cleavage of PAR-1 induces a pro-inflammatory response in cells, whereas APC induces an anti-inflammatory response) (58).

GrK administration is not cytotoxic to endothelial cells and leads to PAR-1-dependent increased expression of the adhesion...
molecules intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) via mitogen-activated protein kinase (MAPK) p38 phosphorylation (39), which facilitate the recruitment and adhesion of circulating leukocytes (59) (Figure 1). Additionally, in vitro studies indicate that endothelial activation is enhanced upon GrK administration to tumor necrosis factor α (TNF-α)-pretreated human umbilical vein endothelial cells (HUVECs), suggesting GrK augments TNF-α-mediated endothelial activation (39). In addition to expression of adhesion molecules, GrK-mediated PAR-1 activation leads to production and secretion of cytokines, thereby promoting inflammation (39).

**Pro-Inflammatory Cytokine Response**

Several granzymes have been reported to modulate the pro-inflammatory cytokine response [e.g. GrA (200-600 nM), GrB (25-100 nM)] (8, 41, 51). In addition to the prior mentioned intracellular modulation of mGrK resulting in release of inflammatory cytokine IL-1β, extracellular human GrK has been reported to cause a pro-inflammatory cytokine response in vitro. This response is observed in monocytes, human lung fibroblasts, HUVECs, human keratinocytes and skin fibroblasts (39, 40, 56, 60). The release of pro-inflammatory cytokines from these cells is dependent on PAR-1 activation and downstream extracellular signal-regulated kinase 1/2 (ERK1/2) and MAPK p38 phosphorylation and independent on nuclear factor-kB (NF-kB) (39, 56, 60) (Figure 1). HUVECs, human keratinocytes, skin fibroblasts and pulmonary fibroblasts shown an enhanced expression of IL-6 upon GrK administration, which may influence inflammation through leukocyte differentiation (39, 40, 56). Likewise, monocyte chemoattractant protein 1 (MCP-1) secretion is enhanced in HUVECs and pulmonary fibroblasts when treated with GrK, stimulating inflammation by attraction of leukocytes (39, 40). Lastly, GrK treatment induces enhanced IL-8 release from human lung fibroblasts (39, 40). These cytokines all promote inflammation by development, recruitment and activation of immune cells (61, 62). Therefore, next to intracellular functioning, the potential of GrK to activate the endothelium and induce a pro-inflammatory cytokine response through PAR-1 point towards a role for GrK in inflammatory diseases. GrK stimulates a pro-inflammatory cytokine response in both human and mice, suggesting an essential role of GrK in the production of cytokines and control of inflammation during evolution. This is further supported by the notion that the GZMA/K locus exists in representative species tracing back to cartilaginous fish (63).

**GRK IN DISEASE**

Similar to other proteases, intracellular and extracellular granzyme levels are increased during several diseases, indicating the significance of progressive granzyme research. Emerging evidence on the pro-inflammatory potential of granzymes further underlines the suggested role of granzymes in disease (8). This is a newly emerging field, most research consists of in vitro studies providing insight into the role of granzymes in disease, including GrK. Human research demonstrates free GrK levels are elevated in several viral and bacterial infections, sepsis (14, 60), burn wounds (56) and airway infections including allergic asthma and acute bronchopneumonia (64) (Table 2).

**Viral Infections**

Cytomegalovirus (CMV) is a herpesvirus affecting primates, including humans (66). As a non-life threatening virus, most infected people do not notice CMV, whereas in immunocompromised patients (e.g. AIDS patients) a CMV infection causes symptoms including diarrhea and fever (66). In human plasma, GrK levels are elevated in patients suffering from CMV infection (23). Moreover, GrK levels are elevated in plasma samples from Dengue fever patients compared to healthy controls (23). Plasma-derived cytotoxic T lymphocytes of mice infected with Chikungunya virus have increased expression of GrK (67). Furthermore, GrK−/− mice have reduced foot swelling.

**TABLE 2 | Intracellular and extracellular GrK in human disease.**

| Disease Status | Extra- or intra-cellular | Description | Reference |
|----------------|--------------------------|-------------|-----------|
| **Viral infection** | | | |
| Influenza A virus | Intracellular | GrK cleaves importin 1α or β in vitro, inhibiting viral replication of influenza A. | (38) |
| Dengue virus | Extracellular | Soluble GrK levels are elevated, suggesting an anti-viral role of GrK in vivo. | (23) |
| Cytomegalovirus | Extracellular | Soluble GrK levels are elevated, suggesting an anti-viral role of GrK in vivo. | (23) |
| **Bacterial infection** | | | |
| Pseudomonas aeruginosa | Extracellular | GrK synthesis occurs after 24h incubation of whole blood with P. aeruginosa. | (65) |
| Sepsis | Extracellular | Free GrK (monomer) is only found in septic patients, compared to the inactive (multimer) form in healthy controls. | (14) |
| **Experimental endotoxemia** | Extracellular | GrK levels are elevated upon LPS injection. | (65) |
| **Lung disease** | | | |
| Airway inflammation (Allergic asthma & Bronchopneumonia) | Extracellular | GrK levels are elevated compared to healthy controls, leading to CCL3 release and recruitment of T cells to the site of inflammation. | (62) |
| **Other** | Extracellular/intracellular | GrK impairs wound healing in mice by promotion of inflammation and inhibiting epithelialization. | (56) |

GrK, granzyme K; CCL3 or MIP-1-alpha, Macrophage inflammatory protein-1α.
compared to GrK\(^{+/+}\) mice, suggesting a pro-inflammatory role for GrK (67). The enhanced production and secretion of GrK in these diseases underlines the potential of GrK to play a role in the immune defense against viral infections. Whether GrK modulates the response to these viral infections and the molecular mechanisms involved remain to be explored.

Influenza A is a recurring virus characterized by fever and coughing which causes epidemics in birds and mammals (68). When challenged with influenza A, WT mice display long-term expression of GrK by antigen-specific CTLs (69). Moreover, GrK was detected at high frequencies in CD8+ T cells derived from GrA\(^{-/-}\)/GrB\(^{-/-}\) mice after challenge with influenza A (70). Influenza A is a negative-strand RNA virus replicated by RNA polymerase in the host cell nucleus through recognition of the nucleoprotein (NP) and viral RNA complex (38). Prior to complex formation, RNA polymerase and NP are transported from the cytoplasm to the nucleus by binding to importin \(\alpha\) or \(\beta\) (38). Human GrK associates to importin \(\alpha\) and cleaves importin \(\alpha\) and \(\beta\) following incubation with K562 cell lysates. Therefore, GrK may inhibit viral replication by cleaving importin \(\alpha\) or \(\beta\), preventing NP/viral RNA complex formation and preventing RNA polymerase recruitment in vitro (38). The finding GrK may inhibit viral replication by its proteolytic capability has yet to be confirmed for humans and mice in vivo.

Furthermore, GrK possibly aids in the clearance of LCMV infection in mice (17). LCMV is a rodent virus which is a widely accepted model to study viral infections. GrA and GrB knockout mice models suggest that GrA and GrB are not imperative for LCMV clearance in mice, in contrast to perforin (17). This, together with the finding that GrK is expressed ex vivo by LCMV-infected mouse-derived CD8+ T cells, led to the hypothesis that GrK might control LCMV clearance in mice (17). LCMV-derived CD8+ T cells expressing GrK but not GrA and GrB are not cytotoxic (17). Accordingly, administration of recombinant GrK is not cytotoxic to EL4 cells in vitro (17). However, recombinant GrK induces production of mature proinflammatory IL-1\(\beta\) in pre-activated PEMØs (macrophages) (17). Similarly, LCMV-derived immune cells and GrA\(^{-/-}\)/GrB\(^{-/-}\) CD8+ cells induce release of IL-1\(\beta\) in LPS-primed PEMØs in the presence of gp33, a LCMV-immunogenic peptide (17). IL-1\(\beta\) may be an important mediator in LCMV infections since mice treated with IL-Ra, a IL-1\(\beta\) receptor antagonist, fail to clear the LCMV infection (17). Combined, these results suggest that clearance of LCMV infection is (at least partly) dependent on GrK-mediated non-cytotoxic mechanisms (17). However, the suggestion that GrK is a key player in LCMV clearance is challenged by an in vivo study on GrK\(^{-/-}\) mice, which show no impaired LCMV clearance upon intraperitoneal injection with LCMV compared to WT mice (48). Moreover, elimination of Ectromelia virus (ECTV) is not impaired in GrK\(^{-/-}\) mice. This suggests GrK does not play an essential role in the anti-LCMV or anti-ECTV immunity (48).

**Bacterial Infections**

Intake of pathogenic bacteria derives from different kinds of sources such as food or water consumption, air, living vectors, or indirect contact. Infections with gram-negative or gram-positive bacteria activate a variety of molecular pathways and symptoms observed in an infected individual (e.g. fever, inflammation, swelling) dependent on the bacterial and cell wall characteristics (e.g lipopolysaccharide (LPS) from the outer cell membrane of gram negative bacteria). More serious bacterial infections can result in septic shock, characterized by organ failure and ultimately lead to death if left untreated.

In sepsis and human experimental endotoxemia, a model for systemic infection, levels of soluble GrK, GrA and GrB, are elevated (14, 60, 71). The elevation of GrK in sepsis is accompanied by a reduced expression of Il1\(\alpha\), the natural inhibitor of GrK, which indicates an increase in the activity of GrK (inverse correlation) (32, 65, 72). Subsequent research showed GrK release in whole blood cultures is restricted to P. aeruginosa, a gram-negative bacterium (73). This suggests that the gram-negative bacterial cell wall, in particular LPS, plays a pivotal role in triggering GrK secretion.

*In vitro* research confirmed this hypothesis. GrK, and its catalytically inactive mutant, GrK-SA, have been shown to bind and modulate LPS – suggesting that LPS binding is independent from GrK’s catalytic activity (60). LPS consists of a lipid that inserts the molecule in the membrane, a core peptide and the O-antigen. Studies focusing on recombinant LPS revealed GrK potentiates LPS by binding to the O-antigen, the outermost part of LPS (60). Recombinant LPS molecules exist in plasma as micelles, with protruding O-antigen faces towards the extracellular space (60). GrK facilitates both removal of individual LPS molecules from micelles by binding to its O-antigen, and their transfer to CD14. LPS and CD14 form a complex that binds to toll-like receptor 4 (TLR4) on the cell membrane, leading to an inflammatory cytokine response (60). Specifically, it was shown in *in vitro* that this leads to TNF-\(\alpha\) release from human primary monocytes (60).

**Airway Inflammation**

In lung diseases such as chronic obstructive pulmonary disease (COPD) (a progressive inflammatory lung disorder characterized by shortness of breath and coughing), hypersensitivity pneumonitis (rare immune system disorder affecting resulting in hypersensitivity to inhaled dust) and allergic asthma (resulting from exposure to allergens e.g. pollen), roles for GrA and GrB have been reported. Less is known about the endobronchial expression and release of GrK in lung disease. In a study involving non-smoking and smoking subjects with or without asthma, bronchopneumonia or COPD, bronchoalveolar lavage fluid (BALF) of acute bronchopneumonia patients showed a 18-fold increase of GrK compared to healthy controls (64). Similarly, in allergic asthma patients an elevation in soluble GrK levels as well as GrK expressing CD8+ T cells in BALF could be observed upon allergen challenge (24 and 72 hour after exposure) (64). Recruitment of GrK expressing CD8+ T cells might be dependent on chemokine c-c motif ligand (CCL)3, a chemokine which is elevated in the BALF of asthma patients following allergen challenge (64). Further, *in vitro* studies demonstrate that extracellular GrK induces cytokine secretion of IL-6, IL-8 (CXCL8) and monocyte chemotactic protein-1 (MCP-1)/CCL2 and proliferation of human lung fibroblasts through a PAR-1
dependent mechanism (40). This suggests GrK may play a role in airway remodeling by augmenting inflammation (40, 64).

**Inflammaging**

Aging and age-related illnesses share similar mechanistic processes converging on inflammation (74). Affecting the immune system, aging results in a chronic low-grade inflammation (inflammaging) that contributes to the pathogenesis of age-related illnesses. Interestingly, a recent study of Mogilenko et al., 2021 identified a subset of clonal GrK⁺ CD8⁺ T cells as conserved hallmark of inflammaging in both mice and humans. In mice of advance age nearly half of all circulatory CD8⁺ T cells acquire an age-associated GrK⁺ CD8⁺ T phenotype indicating the potential impact on aging physiology through GrK secretion. Furthermore, in a healthy human cohort clonal GrK⁺ CD8⁺ T cells increased with age. Like in mice, the cells display elevated EOMES expression levels and a distinct epigenetic landscape. Together, the results suggest that GrK⁺ CD8⁺ T cells as well as GrK itself can be potential targets to address age-associated immune dysfunction (75).

**Thermal Injury**

Healing of thermal injury and burn wounds is often accompanied by inflammation, leading to painful contractures and excessive scarring (76). In humans, levels of extracellular GrK are elevated in acute burn tissues following thermal injury compared to normal tissue (day 2-30 after injury). This is predominantly observed in macrophages (56). Furthermore, after GrK⁻/⁻ mice were subjected to tissue (day 2-30 after injury). This is predominantly observed in acute burn tissues following thermal injury compared to normal thermal injury.

| Process | GrK Role |
|---------|----------|
| Circulatory CD8⁺ T cells | Acquire an age-associated GrK⁺ CD8⁺ T phenotype |
| Extracellular GrK | Elevated in acute burn tissues |
| Thermal injury | Reduced in GrK⁺ mice compared with GrK⁻/⁻ mice |
| Wound healing | Improved in GrK⁺ mice |

GrK⁺ CD8⁺ T cells as conserved hallmark of inflammaging in both mice and humans. In mice of advance age nearly half of all circulatory CD8⁺ T cells acquire an age-associated GrK⁺ CD8⁺ T phenotype indicating the potential impact on aging physiology through GrK secretion. Furthermore, in a healthy human cohort clonal GrK⁺ CD8⁺ T cells increased with age. Like in mice, the cells display elevated EOMES expression levels and a distinct epigenetic landscape. Together, the results suggest that GrK⁺ CD8⁺ T cells as well as GrK itself can be potential targets to address age-associated immune dysfunction (75).

**GRK AS A THERAPEUTIC TARGET**

Since granzymes are associated with several diseases and appear extracellularly, they are considered promising therapeutic targets (8). Several fusion proteins of GrB against solid tumors are in development as therapeutic agents, such as GrB conjugated to VEGF or TNF-α (78). Similarly, inhibition and administration of GrK could provide novel ways to overcome disease.

Inhibition of GrK could be beneficial for diseases in which elevated GrK is associated with unfavorable disease outcomes. For example, GrK inhibition could reduce the release of pro-inflammatory cytokines in allergic asthma. Over the last 25 years, several inhibitors for GrK have been described including physiological inhibitors, and specific and nonspecific synthetic inhibitors (32). Physiological nonspecific inhibitors of GrK include antithrombin III (ATIII) and α-macroglobulin (α-2M) (32), mainly inhibiting thrombin, plasmin, cathepsin G and blood coagulation factors (79, 80). The GrK inhibitory effect of these compounds is elevated when combined with heparin (27, 32). However, only high, non-physiological concentrations of ATIII and α-2M reduce the catalytic ability of GrK (32). Up to date, the only identified specific physiological GrK inhibitor in human plasma is Ip (32). Ip inhibits GrK dose-dependently as well as inhibiting cytokine production (32, 39, 81). Ip contains various chains, one of which is bikunin. Bikunin also circulates as free form in plasma inhibiting GrK at its S1 pocket (32). Administration of (human) Ip in mice, rabbit and rat models ameliorates survival in LPS or bacteria-induced sepsis (82–85). Considering that GrK and Ip levels in plasma of sepsis patients are elevated, these could be used as molecular targets or treatment for sepsis patients (72). Synthetic GrK specific inhibitors include 3,3-diphenylproponyl-Pro-(4-AmPhGly)P(OPh)2 and D-Phe-Pro-Arg-chloromethyl ketone (30, 86, 87). Other general synthetic protease inhibitors (e.g. trypsin inhibitors benzamidine and aprotinin) also inhibit GrK, as well as GrA activity (32, 87, 88).

In infections with gram-negative bacteria, the unfavorable pro-inflammatory cytokine response cannot be decreased by an inhibitor targeting GrKs active site, as GrK induces the pro-inflammatory cytokine response by binding to LPS and transferring LPS to CD14. Monoclonal antibodies that interfere in the interaction between GrK and LPS are proposed as potent mediators (60). This approach could also be valuable in other diseases in which GrK plays a pathogenic role independent of its catalytic activity. To date however, no monoclonal antibodies to target GrK therapeutically have been reported. Moreover, targeting proteases that activate PAR-1 to stimulate the inflammatory response might thus provide an efficient therapeutic strategy as PAR-1 adopts a dual role in disease, both protective and pro-inflammatory (39).

Furthermore, GrK could be targeted by attenuating gene expression. Gene expression can be influenced by small interfering RNAs (siRNAs) or microRNAs (miRNAs). Targeted siRNAs are already in use to knockdown granzyme expression, for example in granzyme C research (89). Next to siRNAs, miRNAs interfere in the post-translational modification of newly synthesized granzymes, including GrK. Recently, miRNA-145 has been reported to be valuable in myocardial ischemia/reperfusion (I/R) injury mouse models by regulating the expression of GrK. In this study, the protective role of
miRNA-145 against I/R injury by regulating the expression of GrK with the treatment of anesthetic sevoflurane was investigated. In ischemia, miRNA-145 levels are decreased, whilst mGrK levels are upregulated. As GrK is a potential target gene of miRNA-145, miRNA-145 could inhibit GrK expression. Upon treatment with sevoflurane, miRNA-145 levels are upregulated and GrK expression is reduced – relieving I/R injury (90). Interestingly, miRNA-145 significantly elevates functioning of the left ventricle and decreases the myocardial infarct size suggesting that downregulation of GrK and upregulation of miRNA-145 may be protective of I/R injury (90).

GrK administration could be beneficial for diseases in which GrK expression is associated with favorable disease outcomes (e.g. recovery). This includes for example influenza A infection. Administration of exogenous granzymes has been studied extensively for human GrB in vitro and in mice using recombinant GrB coupled to the Lewis Y-binding antibody dsFv-B3 or using an anti-HER2 antibody against HER2 tumors (91, 92). Through this granzyme-antibody construct, GrB can be effectively internalized both in vivo and in vitro (92). Illustratively, by conjugating GrK to an anti-sialic acid antibody, the influenza A receptor, GrB delivery could be adjusted to GrK.

CONCLUSION

After twenty years of GrK research, new roles are emerging complementing GrK’s traditionally described role in cytotoxicity. Most current studies on GrK discussed in this review are either in vitro (e.g. cell-culture, binding assays) using human or mouse GrK or in vivo animal studies (e.g. GrK−/− mice). Both in vitro and in vivo studies identified roles in the modulation of inflammation, inhibition of viral replication and LPS potentiation. Furthermore, GrK inhibition and stimulation have been suggested for a variety of disease statuses as therapeutic targets, including inflammatory disease and cancer. Whilst no longer being considered an ‘orphan granzyme’ at present, much of GrK functioning and molecular mechanisms remain to be discovered.

Targeting GrK therapeutically remains a challenge due to a lack of in vivo studies involving GrK in disease and GrKs dual role in pathology (for example in viral replication inhibition and airway inflammation). To meet the latter difficulty, GrK-SA may be used as a substitute for active GrK in therapy. This way, the pathological effect dependent on the active site of GrK should be reduced, thereby minimizing adverse effects of GrK administration. Further research is required to i) explore the controversy around GrKs cytotoxic potential ii) review the inhibitory effect of GrK on influenza A replication in vivo and iii) investigate the curative role of GrK(SA) upon inhibition (with synthetic or physiological inhibitors) or administration in thermal injury and airway inflammation.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

KD received funding for het PhD studies from the Gates Cambridge Scholarship (OPP1144).

REFERENCES

1. Grossman WJ, Revell PA, Lu ZH, Johnson H, Bredemeyer AJ, Ley TJ. The Orphan Granzymes of Humans and Mice. Curr Opin Immunol (2003) 15:544–52. doi: 10.1016/s0952-7915(03)00099-2
2. Voskoboinik I, Whistock JC, Trapani JA. Perforin and Granzymes: Function, Dysfunction and Human Pathology. Nat Rev Immunol (2015) 15:388–400. doi: 10.1038/nri3839
3. van Domselaar R, Bovenschen N. Cell Death-Independent Functions of Granzymes: Hit Viruses Where it Hurts. Rev Med Virol (2011) 21:301–14. doi: 10.1002/rmv.697
4. Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol (2007) 35:495–516. doi: 10.1080/01926230701320337
5. Romero V, Andrade F. Non-Apoptotic Functions of Granzymes. Tissue Antigens (2008) 71:409–16. doi: 10.1111/j.1399-0039.2008.01013.x
6. Frolich CJ, Pardo J, Simon MM. Granule-Associated Serine Proteases: Granzymes Might Not Just Be Killer Proteases. Trends Immunol (2009) 30:117–23. doi: 10.1016/j.it.2009.01.002
7. van Daalen KR, Reineveld JF, Bovenschen N. Modulation of Inflammation by Extracellular Granzyme a. Front Immunol (2020) 11:931. doi: 10.3389/fimmu.2020.00931
8. Wensink AC, Hack CE, Bovenschen N. Granzymes Regulate Proinflammatory Cytokine Responses. J Immunol (2015) 194:491–7. doi: 10.4049/jimmunol.1401214
9. Bovenschen N, Spikkers SNM, Wensink AC, Schellens IMM, van Domselaar R, van Baarlen D. Elevated Granzyme M-expressing Lymphocytes During Cytomegalovirus Latency and Reactivation After Allogeneic Stem Cell Transplantation. Clin Immunol (2014) 150:1–11. doi: 10.1016/j.clinim.2013.11.005
10. van Domselaar R, de Poort SAH, Remmerswaal EBM, Lai KW, ten Berge IJM, Bovenschen N. Granzyme M Targets Host Cell Hnnp K That is Essential for Human Cytomegalovirus Replication. Cell Death Differ (2013) 20:419–29. doi: 10.1038/cdd.2012.132
11. van Domselaar R, Quadir R, van der Made AM, Broekhuizen R, Bovenschen N. All Human Granzymes Target Hnnp K That is Essential for Tumor Cell Viability. J Biol Chem (2012) 287:22854–64. doi: 10.1074/jbc.M112.365692
12. Bovin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular Versus Extracellular Granzyme B in Immunity and Disease: Challenging the Dogma. Lab Invest (2009) 89:1195–220. doi: 10.1038/latinvest.2009.91
13. Turner CT, Lin D, Granville DJ. Granzyme B in Skin Inflammation and Disease. Matrix Biol (2019) 75-76:126–40. doi: 10.1016/j.matbio.2017.12.005
14. Rucevic M, Fast LD, Jay GD, Trespalcios FM, Sucov A, Siryaporn E, et al. Altered Levels and Molecular Forms of Granzyme K in Plasma From Septic Patients. Shock (2007) 27:488–93. doi: 10.1097/01.shk.0000246905.24895.e5
15. Hermsen CC, Konijnenberg Y, Mulder L, Loë C, Van Deuren M, Van Der Meer JWM, et al. Circulating Concentrations of Soluble Granzyme A and B Increase During Natural and experimental Plasmodium Falciparum Infections. Clin Exp Immunol (2003) 132:467–72. doi: 10.1046/j.1365-2249.2003.02160.x
16. Garcia-Laorden MI, Blok DC, Kager LM, Hoogendijk AJ, van Mierlo GJ, Lede IO, et al. Increased Intra- and Extracellular Granzyme Expression in Patients With Tuberculosis. Tuberculosis (2015) 95:575–80. doi: 10.1016/j.tube.2015.05.016
driven Inflammatory Diseases. *Thromb J* (2019) 17:4. doi: 10.1186/s12959-019-0194-8

58. Ratafia K, M. Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway. *Science* (2002) 296:1880–2. doi: 10.1126/science.1071699

59. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the Site of Inflammation: The Leukocyte Adhesion Cascade Updated. *Nat Rev Immunol* (2007) 7:678–89. doi: 10.1038/nri2156

60. Wensink AC, Kemp V, Fermie J, Garcia Laorden MI, van der Poll T, Hack CE, et al. Granulocyte K Synergistically Potentiates LPS-induced Cytokine Responses in Human Monocytes. *Proc Natl Acad Sci* (2014) 111:5974–9. doi: 10.1073/pnas.1317347111

61. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of Macrophage Chemotactic Protein-1 in Macrophage Recruitment, Angiogenesis, and Survival in Human Breast Cancer. *Cancer Res* (2000) 6:3282–9.

62. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farmanar C, II-6: A Regulator of the Transition From Neutrophil to Monocyte Recruitment During Inflammation. *Trends Immunol* (2003) 24:25–9. doi: 10.1016/s1471-4906(02)00113-3

63. Akula S, Thorpe M, Boinapally V, Hellman L. Granule Associated Serine Proteases of Hematopoietic Cells - An Analysis of Their Appearance and Diversification During Vertebrate Evolution. *PloS One* (2015) 10:e0143091. doi: 10.1371/journal.pone.0143091

64. Bartsch K, Klug A, Julius P, Kuepper M, Lommatzsch M, Sparmann G, et al. Granulyme K: A Novel Mediator in Acute Airway Inflammation. *Thorax* (2008) 63:1006–11. doi: 10.1136/thx.2007.091215

65. Lim Y, Bendelka K, Opal SM, Sarypon E, Hixson DC, Palardy JE. Correlation Between Mortality and the Levels of Inter-Alpha Inhibitors in the Plasma of Patients With Severe Sepsis. *J Infect Dis* (2003) 188:919–26. doi: 10.1086/377642

66. Cohen JL, Ralph Corey G. Cytomegalovirus Infection in the Normal Host. *Medicine* (1985) 64:100–14. doi: 10.1097/00005792-198503000-00003

67. Wilson JAC, Prow NA, Schroder WA, Ellis J, Cumming HE, Nourshargh S, et al. Alpha-2-Macroglobulin Functions as an Inhibitor of Fibrinolytic, Clotting, and Neutrophilic Proteases in Sepsis: Studies Using a Baboon Model. *Infect Immun* (1993) 61:3035–43. doi: 10.1128/IAI.61.12.3035-3043.1993

68. Logdon AF, Erickson MA, Chen X, Qi J, Lim Y-P, Stonestreet BS, et al. Inter-Alpha Inhibitor Proteins Attenuate Lipopolysaccharide-Induced Blood-Brain Barrier Disruption and Downregulate Circulating Interleukin 6 in Mice. *J Cereb Blood Flow Metab* (2020) 40:1090–102. doi: 0.1027/02717819.19589465

69. Singh K, Zhang LX, Bendelka K, Heath R, Murphy S, Sharma S, et al. Inter-Alpha Inhibitor Protein Administration Improves Survival From Neonatal Sepsis in Mice. *Pediatr Res* (2010) 68:242–7. doi: 10.1203/PDR.0b013e3181e9dfb0

70. Nakamura M, Takeuchi T, Yatagi Y, Naito K, Shirakawa K, Hosaka Y, et al. The Modified Light Chain of Inter-Alpha Inhibitor Antibody Fusion Protein, MR1007, Improves Survival in the Rabbit Sepsis Models. *Crit Care* (2007) 11:4. doi: 10.1186/cr9583

71. Yang S, Lim Y-P, Zhou M, Salvemini P, Schwinn H, Josic D, et al. Administration of Human Inter-Alpha Inhibitors Maintains Hemodynamic Stability and Improves Survival During Sepsis. *Crit Care Med* (2002) 30:617–22. doi: 10.1097/00003246-200203000-00021

72. Wu R, Cui X, Lim Y-P, Bendelka K, Zhou M, Simms HH, et al. Delayed Administration of Human Inter-Alpha Inhibitor Proteins Reduces Mortality in Sepsis. *Crit Care Med* (2004) 32:1747–52. doi: 10.1097/00003158-200406000-00121

73. Jackson DS, Fraser SA, Ni LM, Kam CM, Winkler U, Johnson DA, et al. Synthesis and Evaluation of Diphenyl Phosphonate Esters as Inhibitors of the Trypsin-Like Granzymes A and K and Mast Cell Tryptase. *J Med Chem* (1998) 41:2289–301. doi: 10.1021/jm970543s

74. Wiharm E, Tschopp J, Jenne DE. Biological Activities of Granzyme K are Driven Inflammatory Diseases. *Nat Biotechnol* (2019) 37:593–7. doi: 10.1038/s41581-019-01200-4

75. Trapani JA. Granzymes, Cytotoxic Granules and Cell Death: The Early Work of Dr. Jurgen Tschopp. *Cell Death Differ* (2012) 19:21–7. doi: 10.1038/cdd.2011.156

76. Getachew Y, Stout-Delgado H, Miller BC, Thiele DL. Granzyme C Supports Efficient CTL-mediated Killing Late in Primary Alloimmune Responses. *J Immunol* (2008) 181:7780–7. doi: 10.4049/jimmunol.181.11.7810

77. Qi Z, Li S, Su Y, Zhang J, Kang Y, Huang Y, et al. Role of micro-RNA-145 in Protection Against Myocardial Ischemia/Reperfusion Injury in Mice by Modulating Expression of GZMK With the Treatment of Seluvorane. *J Cell Physiol* (2019) 234:16526–39. doi: 10.1002/jcp.28323

78. Kurschus FC, Kleinschmidt M, Fellows E, Dormnark K, Rudolph R, Lilie H, et al. Targeting of Tumors by Redirected Granzyme B in the Absence of Perforin. *FEBS Lett* (2004) 562:87–92. doi: 10.1016/j.febslet.20030103.085017-5

79. Zhao J, Zhang L-H, Jia L-T, Zhang L, Xu Y-M, Wang Z, et al. Secreted Antibody/Granzyme B Fusion Protein Stimulates Selective Killing of HER2-overexpressing Tumor Cells. *J Biol Chem* (2004) 279:21343–8. doi: 10.1074/jbc.M312648200

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer DK declared a past co-authorship with one of the authors NB to the handling editor.

Copyright © 2021 Bouwman, van Daalen, Cnuko, ten Broeke and Bovenschen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.